Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Alpha-1 Adrenergic Antagonist (1) ·
Antidepressant (1) ·
Anxiolytic (1) ·
Beta Blocker (4) ·
Cardioselective (β1) (2) ·
Cardioselective (β1) + vasodilator (1) ·
Combined cholinesterase inhibitor + NMDA antagonist (1) ·
Dual orexin receptor antagonist (DORA) (3) ·
GABA-A positive allosteric modulator (oral) (1) ·
Neuroactive steroid (1) ·
Non-selective (1) ·
Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) ·
PDE5 Inhibitor (4) ·
SSRI (1) ·
the first approved (1) ·
wake-promoting agent (1)
mechanism:
None (1) ·
Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) ·
Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) ·
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) ·
Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) ·
Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. (1) ·
Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1)
uses:
None (1) ·
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
Postpartum depression (PPD) in adults (FDA-approved 2023) (1) ·
'"`UNIQ--vote-00000040-QINU`"' (1) ·
'"`UNIQ--vote-00000468-QINU`"' (1) ·
'"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1) ·
'"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) ·
'"`UNIQ--vote-00000669-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)
starting dose:
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) ·
10 mg ~1 h before sexual activity (1) ·
100 mg ~15 min before sexual activity (1) ·
10–40 mg (situational anxiety); 40 mg BID (HTN) (1) ·
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
25 mg (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) ·
5 mg daily (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
50 mg PO once daily with fatty food in the evening × 14 days (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1)
preparations:
1, 2, 5 mg caps (1) ·
10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) ·
2.5, 5, 10, 20 mg tabs (2) ·
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) ·
20 mg, 25 mg, 30 mg capsules (1) ·
25 mg, 50 mg tablets (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) ·
5 mg, 10 mg tablets (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1) ·
5, 10 mg tabs (1) ·
50, 100, 200 mg tabs (1) ·
7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) ·
75 mg, 150 mg tablets (1) ·
Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)
fda max:
10 mg/d (1) ·
100 mg/d (ED); 20 mg TID (PAH) (1) ·
150 mg/d (1) ·
20 mg/d (3) ·
20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) ·
200 mg/d (1) ·
200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1) ·
28/10 mg/d (1) ·
40 mg/d (2) ·
400 mg/d (1) ·
50 mg/d (1) ·
50 mg/d × 14 d (1) ·
640 mg/d (HTN); 240 mg/d (migraine) (1)
routes:
onset:
1–2 h (2) ·
1–2 h (PO), immediate (IV) (1) ·
1–2 h (PO); immediate (IV) (1) ·
30 min (1) ·
30–60 min (1) ·
30–90 min (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Component effects accumulate over weeks (1) ·
Day 3 of dosing in trials; sustained through day 45 (1) ·
~15 min (fastest of the PDE5 inhibitors) (1) ·
~30 min (4) ·
~30-60 min (1)
duration:
halflife:
2–3 h (1) ·
3–6 h (1) ·
3–7 h (1) ·
4–5 h (1) ·
9–12 h (1) ·
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) ·
~12 hours (1) ·
~16-23 hours (1) ·
~17-19 hours (longer than daridorexant) (1) ·
~17.5 h (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~4 h (1) ·
~5 h (1) ·
~60–80 h (memantine); ~70 h (donepezil) (1) ·
~7.1 hours (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1)
bioavailability:
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Adequate (food-dependent, must take with fatty meal) (1) ·
Rapid absorption; absolute bioavailability not formally established (1) ·
Reasonable (not formally established as a percentage) (1) ·
~100% both components (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~15% (extensive hepatic first-pass) (1) ·
~25% (extensive hepatic first-pass) (1) ·
~40% (1) ·
~44% (1) ·
~50% (1) ·
~60% (1) ·
~62% (1) ·
~82% (1) ·
~90% (low first-pass) (1) ·
~95% (1)
pregnancy:
Category B (3) ·
Category C (5) ·
Category C (not relevant; not used in women) (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data; avoid (3) ·
Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) ·
Limited data; pregnancy exposure registry available (1) ·
Not relevant (geriatric problem) (1)
legal: (Click arrow to add another value)
Showing below up to 16 results in range #1 to #16.